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Abstract
The aim of this study is to access the feasibility, toxicity profile, and tumour outcome of an organ preservation curative approach in non-metastatic 
muscle-invasive bladder cancer.
A retrospective analysis was conducted on patients affected by M0 bladder cancer, who refused cystectomy and were treated with a curative 
approach. The standard bladder preservation scheme included maximal transurethral resection of bladder tumour (TURBT) and combination 
of radiotherapy and platin-based chemotherapy, followed by endoscopic evaluation, urine cytology, and instrumental evaluation.
Thirteen patients fulfilled the inclusion criteria. TNM stage was cT2cN0M0 and cT2cNxM0, in 12 and one patients, respectively. All patients 
had transitional cell cancer. Twelve patients completed the whole therapeutic programme (a bimodal treatment without chemotherapy for 
one patient). Median follow-up is 36 months. None of the patients developed severe urinary or intestinal acute toxicity. In 10 patients with a 
follow-up > 6 months, no cases of severe late toxicity were observed. Response evaluated in 12 patients included complete response and 
stable disease in 11 patients (92%), and one patient (8%), respectively. At the time of data analysis (March 2016), 10 patients (77%) are alive 
with no evidence of disease, two patients (15%) died for other reasons, and one patient has suspicious persistent local disease.
The trimodality approach, including maximal TURBT, radiotherapy, and chemotherapy for muscle-invasive bladder cancer, is well-tolerated 
and might be considered a valid and feasible option in fit patients who refuse radical cystectomy. 
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Introduction
The standard treatment for muscle-invasive bladder cancer remains radical cystectomy, with removal of bladder, regional lymph nodes 
(extended lymph node dissection) and surrounding structures (uterus or prostate gland), with urinary diversion [1–2]. This procedure 
is still associated with complication rates of up to 30% and, moreover, urinary diversion has a great impact on long-term urinary, gas-
trointestinal, and sexual function, decreasing significantly the patient’s quality of life [3–4].
Two cohorts of patients could benefit from a conservative approach: patients with a limited disease who wish to avoid aggressive surgery 
and patients with severe comorbidities who are not candidates for radical cystectomy.
Single modality bladder-preservation treatment consisting of transurethral resection of bladder tumour (TURBT), chemotherapy, or radio-
therapy yields inferior results in terms of local tumour control and long-term survival [5–6].
No randomised studies comparing radical cystectomy and the bladder-sparing approach have been completed: the SPARE (Selective blad-
der Preservation Against Radical Excision) trial which expected to randomly compare radical cystectomy versus bladder preservation has 
been closed due to poor accrual [7]. Several prospective studies has been conducted over the past two decades showing survival rates of 
a trimodality approach, comparable to those of radical cystectomy or neoadjuvant chemotherapy followed by cystectomy series [8–11]. This 
combined treatment is based on maximal TURBT, followed by radiotherapy and concurrent chemotherapy.
Long-term data, recently published by the Radiation Therapy Oncology Group (RTOG), are important in establishing selective bladder-
preserving treatments as a safe and effective alternative to cystectomy [12].
Consequently, bladder preservation is now considered as an option by the guidelines of the major scientific societies (National 
Comprehensive Cancer Network, European Association of Urology EAU) for selected patients [13–14]. However, our recent sur-
vey showed that bladder preservation is rarely used in Lombardy (Milan area), despite the availability of the latest radiotherapy 
technologies and the presence of a urology tumour board in at least half of the centres [15]. Our purpose, at the European Institute 
of Oncology, Milan, was to retrospectively analyse the feasibility, toxicity profile, and tumour control of the trimodality approach in 
non-metastatic muscle-invasive bladder cancer.
Material and methods
The inclusion criteria in this retrospective study were as follows: (1) non-metastatic bladder cancer patients who refused cystectomy 
or were unfit for surgery; (2) patients treated with a trimodality approach, based on a combination of maximal TURBT, radiotherapy, 
and chemotherapy, with a curative intent; (3) written consensus for the treatment; (4) consent for the use of the data for educational and 
research purposes. 
We retrospectively reviewed the medical records, treatments charts, radiotherapy plans, and follow-up appointments. In cases of missing 
follow-up data, the patients or their family doctors were contacted. 
A radiological total-body evaluation was performed at the time of diagnosis to exclude other sites of disease. The approach was dis-
cussed, in all cases, by the institutional multidisciplinary tumour board. After the first TURBT showing muscle-invasive bladder cancer 
(> T2), the trimodality regimen was undertaken including the second maximal TURBT followed by radiation therapy + concomitant 
chemotherapy and evaluation (urine cytology, endoscopic evaluation, and radiological examination). 
At the conclusion of the whole treatment, all patients were radiologically evaluated and, in cases of no evidence of disease, follow-up was 
undertaken. 
Evaluation of acute and late toxicity was performed according to Common Terminology Criteria for Adverse Events (CTCAE v4.0) and 
the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) scoring systems 
[16–17].
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Results
Thirteen patients met the criteria of our study (five females and eight males, median age 65 years at the time of diagnosis) (Table 1). All 
patients were treated in our Institute, between June 2006 and January 2016.
The initial stage, according to the TNM stage system, was defined as cT2 cN0 for 12 patients, cT2 cNx for one patient with two suspicious 
pelvic enlarged nodes (about 1 cm diameter) on the staging abdominal CT with contrast. Non-metastatic disease was confirmed in all 
patients. Histology included transitional cell cancer in all cases.
Table 1. Patient, tumour, and maximum toxicity evaluated during 
chemoradiotherapy.
Patients N patients (tot 13) Percentage
Patient characteristics
Age (years)
Mean
Range
Gender
Male
Female
Smoker
Yes
No 
Unknown
65
42–80
8
5
8 (4 ex-smoker)
2
3
61.5%
38.5%
61.5%
15.4%
23%
Tumour characteristics
Histology
Transitional cell cancer
Primary tumour stage
T2
T3
T4
Regional lymph node stage
N0
Nx
Hydronephrosis
Yes
No
13
13
–
–
12
1
1
12
100%
100%
–
–
92%
8%
8%
92%
Toxicity
RTOG/EORTC scale (15)
Genitourinary
Grade 0
Grade 1 
Grade 2
Grade 3
Gastrointestinal
Grade 0
Grade 1 
2
7
4
–
5
8
15%
54%
31%
–
61.5%
38.5%
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Table 1. (Continued.)
Toxicity
CTCAE v4.0 (14)
Urinary
Grade 0
Grade 1
Grade 2
Gastrointestinal
Grade 0
Grade 1
Anaemia
Grade 0
Grade 1
Grade 3
Asthenia
Grade 0
Grade 1
Grade 2
Leucopenia
Grade 0
Grade 1
Grade 2
Thrombocytopenia
Grade 0
Grade 1
Nausea
Grade 0
Grade 1
Pelvic pain
Grade 0
Grade 2
Alopecia
Grade 0
Grade
2
6
5
7
6
10
2
1
7
4
2
10
2
1
12
1
8
5
11
2
12
1
15.4%
46.1%
38.5%
54%
46%
77%
15.4%
7.6%
53.6%
31%
15.4%
77%
15.4%
7.6%
92%
8%
61.5%
38.5%
84.6%
15.4%
92%
8%
In 10 patients, bladder preservation was administered for patients’ choice. In the other three patients, the conservative programme was 
chosen for clinical reasons.
Eleven patients completed the trimodality programme, including maximal TURBT followed by external radiation therapy and concomitant 
chemotherapy. One patient, affected by an important psychiatric disease, did not finish the whole programme, and we considered the 
treatment ended at the 24th fraction of radiotherapy. 
In one patient with cardiac disorders (arrhythmia requiring pace-maker) no chemotherapy was administered during radiotherapy. 
The external radiotherapy included the whole pelvis. In the initial study period, two patients were treated with three-dimensional (3D) 
conformal external beam radiotherapy through a four-field box technique. The following 11 patients underwent image-guided intensity-
modulated radiotherapy (IG-IMRT), all with daily fractions in five consecutive days each week (Figure 1). 
The treatment volumes included the bladder (with a median dose of 56 Gy), pelvic lymph nodes (with a median dose of 49 Gy) and a boost on 
the site of previous tumour (with a median dose of 62 Gy), determined by computed tomography (CT) scan, clinical information (pre-TURBT 
data, TURBT report, etc.) and magnetic resonance imaging (MRI), if available. IG-IMRT was performed on the outpatient basis. 
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As radiosensitising chemotherapy was employed weekly cisplatin (20 mg/m2/d, one day per week) or carboplatin (area under curve, one 
day per week) in nine and three patients, respectively. Carboplatin was used in patients with renal insufficiency or with another comorbidity 
contraindicating cisplatin use.
Six patients received adjuvant chemotherapy with cisplatin and gemcitabine for two or three courses, following the therapeutic scheme 
showed in Figure 2.
Considering the recent review published by Ploussard et al., illustrating not univocal data about the benefit of adjuvant chemotherapy [18], 
and according to EAU Guidelines [14], the following six patients received only chemotherapy concomitant to radiotherapy.
Two months after the completion of chemoradiotherapy, endoscopic evaluation (cystoscopy or TURBT), and urine cytology were 
performed. 
During concomitant chemoradiotherapy, none of the patients developed acute G3–G4 urinary or gastroenteric toxicity. We observed neither 
an increase in grade 3–4 haematological toxicity and neuropathy with concurrent chemotherapy nor a decrease in treatment completion 
rates caused by cumulative toxicity. 
Figure 1. Dose distribution and volumes of IG-IMRT plan with the concomitant irradiation of lymph nodes of the small pelvis, whole bladder and 
a simultaneous concomitant boost to the site of the bladder tumour.
Figure 2. Schematic representation of the decision–making process in patients treated with bladder-sparing approach.
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One patient, affected concomitantly by multiple myeloma, showed a G3 haematological event and interrupted adjuvant chemotherapy after 
one course to receive support therapy. During adjuvant chemotherapy, one patient experienced a pulmonary embolism and one patient 
renal failure treated with adequate symptomatic therapy.
In 10 patients with a follow-up longer than 6 months, no cases of G3–G4 genitourinary and gastrointestinal toxicity were reported. The 
median follow-up is 36 months (range 2–101 months). 
Twelve patients were evaluable for clinical response. Complete tumour response at the first follow-up, considered as the negativity of endo-
scopic examination and urinary cytology, was observed in 11 patients (92%); persistent bladder disease in one patient (8%), evidenced at 
the first endoscopic evaluation. Progressive disease was observed in none of the patients. One patient developed, after 7 months, an in situ 
bladder recurrence and was treated with BCG (bacillus Calmette-Guérin) instillations. One patient experienced a local invasive bladder 
relapse, 9 months after the end of the trimodality treatment, and, consequently, underwent successful salvage cystectomy. 
At the time of data analysis (March 2016), the status can be defined in all patients. Out of 13 patients, 10 patients (77%) are alive without 
evidence of disease, nine of them (69%) retain an intact bladder; one patient, with a suspect of persistent bladder tumour, is waiting for 
diagnostic TURBT; two patients (15%) died, one for cardiovascular event (the same patient who interrupted chemoradiotherapy for psychi-
atric disease), and one for multiple myeloma.
Both of these two death cases are part of the three patients in which the conservative treatment was chosen for important comorbidities. 
The results observed in this patient subgroup were determined by underlying disease, even if the patient, who underwent bimodal treatment 
without chemotherapy, is still alive without evidence of disease after 7 months of follow-up.
The patient with cNx stage at diagnosis is, at the time of data analysis, alive retaining an intact bladder and without evidence of disease 
after a follow-up of more than 8 years.
Discussion
Our single-institutional study showed that bladder preservation approach can allow the maintenance of a well-functioning organ in a high 
percentage of selected patients with MIBC. Indeed, 69% of all our patients are alive with no evidence of cancer and with intact well-
functioning urinary bladder at median follow-up of 37 months. These figures are similar to those observed in large surgical series and 
other bladder preservation reports [8–9].
We are aware of numerous drawbacks of our series including, apart from the fact it was a unicenter study, low number of patients, long 
accrual time, and retrospective character. However, to the best of our knowledge, this is one of the first reports on bladder preserva-
tion from Lombardy showing feasibility and good results, in particular, in fit patients (8 out of 10 fit patients, i.e., 80%, remain alive with 
intact bladder). We do believe our experience will encourage other multidisciplinary teams to consider bladder preservation in selected 
fit patients [15].
The long accrual time observed in our study reflects the common issue of the treatment choice in muscle-invasive bladder cancer. This is 
probably due to the poor spread of conservative treatments for invasive bladder cancer in our clinical practice despite numerous recent 
reviews showing encouraging results of trimodality therapy in selected patients [19–22].
In the absence of randomised trials, it is difficult to compare bladder preservation with standard cystectomy, because of the wide het-
erogeneity in patient selection. Interestingly, a recent systematic review of clinical retrospective and prospective trials including 13,396 
patients, showed the median five-year overall survival rate of 57% in the trimodality group, when compared with 52% (p = 0.04), 51% 
(p = 0.02), and 53% (p = 0.38) in the whole group receiving radical cystectomy or the group treated with radical cystectomy alone or 
radical cystectomy+chemotherapy, respectively [10]. Indeed, some investigators ask the provocative question on the organ-sparing 
multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? [23]. 
The ideal candidate for bladder preservation are fit patients with a small tumour (less than 5 cm), unifocal, no microscopic residual after 
TURBT, the absence of ureteral obstruction or hydronephrosis, no association with in situ carcinoma (accurately diagnosed by biopsies 
of suspicious areas and analysis of histology of previous TURBT) no evidence of pelvic lymph node disease [24–25]. A recent review 
Cl
in
ic
al
 S
tu
dy
 7 www.ecancer.org
ecancer 2016, 10:657
published by Smith et al. shows that 10–15% of medically operable patients are good candidates for bladder preservation [21]. In our 
series, all patients met the criteria for the conservative treatment as alternative to radical cystectomy. 
The toxicity of trimodality approach, employed in our study, was acceptable with no direct radiotherapy-related severe events. Except in 
studies using neoadjuvant or adjuvant chemotherapy, where toxicity seems higher, this rate ranged from 10% to 36%, while the majority 
(80–90%) of patients did complete the entire course of treatment. The main toxicities are haematological, gastrointestinal, and genitouri-
nary. Neuropathy may be reported in cases of cisplatin-based concurrent chemotherapy. The BC2001 trial reported neither an increase in 
G3–G4 toxicity with concurrent chemotherapy compared with radiotherapy alone nor a decrease in radiotherapy completion rates caused 
by toxicity [25]. 
In the earlier literature series, cystectomy for contracted bladder was necessary in up to 2% of patients receiving a conservative approach 
[21]. In our patients, the complications have been observed predominantly during adjuvant chemotherapy (G3 myelotoxicity, renal failure, 
and lung thromboembolism), confirming higher toxicity of concomitant and adjuvant chemotherapy in respect of concomitant only che-
motherapy in bladder cancer preservation; this finding confirms the fragile general conditions of the bladder cancer patients. Indeed, the 
most recent bladder preservation reports claim that TURBT followed by concomitant chemoradiotherapy (with no adjuvant or neoadjuvant 
chemotherapy) may be considered the optimal approach in terms of tolerability and efficacy [26].
From our limited experience, we learnt two essential assumptions: first, patients’ good compliance is fundamental during the active 
treatment and subsequently, because of the need both of prompt salvage cystectomy in cases of no tumour response or local failure, 
and of lifelong surveillance; second, in such an assessment, a close and continuous collaboration between Urologists, Medical Oncolo-
gists and Radiation Oncologists becomes of extreme importance, in order to reach an optimal multidisciplinary approach. In Lombardy, 
a prospective observational study on the bladder preservation has been just undertaken reinforcing uro-oncology teamwork.
Conclusion
In conclusion, the trimodality approach including maximal TURBT, radiotherapy, and chemotherapy for muscle-invasive bladder cancer, in 
patients who refuse radical cystectomy or are unfit for surgery, could be considered as a good and feasible therapeutic option and results 
in a low rate of acute and late toxicity.
Long-term follow-up and more prospective multicentre research are needed to confirm the results of our retrospective study.
Abbreviations used: TURBT, transurethral bladder tumour resection; G, grade; Gy, Grey, IG-IMRT, image-guided intensity-modulated 
radiotherapy, CT, computed tomography; RT, radiation therapy.
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